Hyeon-Jeong Yoon

Prof. Hyeon-Jeong Yoon

Auto-generated profile, based on publicly available information

Prof. Hyeon-Jeong Yoon


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HYHyeon-Jeong Yoon
Hyeon-Jeong Yoon
EJEnying Jiang
Enying Jiang
NLN/A Liu
N/A Liu
HJHui Jin
Hui Jin
,Y, Yoon
, Yoon
KYKyung Chul Yoon
Kyung Chul Yoon
This study aims to investigate the effect of the selective MT2 receptor agonist, IIK7, on corneal autophagy and apoptosis, aiming to reduce corneal epithelial damage and inflammation from blue light exposure in mice. Eight-week-old C57BL/6 mice were divided into BL-exposed (BL) and BL-exposed with IIK7 treatment (BL + IIK7 group). Mice underwent blue light exposure (410 nm, 100 J) twice daily with assessments at baseline and on days 3, 7, and 14. Corneal samples were analyzed for MT2 receptor expression, autophagy markers (LC3-II and p62), and apoptosis indicators (BAX expression and TUNEL assay). Then, mice were assigned to normal control, BL, and BL + IIK7. Ocular surface parameters, including corneal fluorescein staining scores, tear volume, and tear film break-up time, were evaluated on days 7 and 14. On day 14, reactive oxygen species (ROS) levels and CD4+ IFN-γ+ T cells percentages were measured. The BL group exhibited higher LC3-II and p62 expression, while the BL + IIK7 group showed reduced expression (p < 0.05). The TUNEL assay showed reduced apoptosis in the BL + IIK7 group compared to the BL group. ROS levels were lower in the BL + IIK7 group. The BL + IIK7 group showed improved ocular surface parameters, including decreased corneal fluorescein staining and increased tear volume. The percentages of CD4+ IFN-γ+ T cells indicated reduced inflammatory responses in the BL + IIK7 group. The MT2 receptor agonist IIK7 regulates corneal autophagy and apoptosis, reducing corneal epithelial damage and inflammation from blue light exposure.

1 January 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JMJayoung Moon
Jayoung Moon
EJEnying Jiang
Enying Jiang
NLN/A Liu
N/A Liu
HJHui Jin
Hui Jin
,Y, Yoon
, Yoon
KYKyung Chul Yoon
Kyung Chul Yoon
Background/Objectives: This study aimed to evaluate the therapeutic effects of combined 5% lifitegrast (LF) and tocopherol (TCP) eye drops in a murine experimental dry eye (EDE) model. Methods: Female C57BL/6 were divided into seven groups: untreated controls, EDE control, EDE + 0.05% cyclosporin A (CsA), EDE + tocopherol (TCP), EDE + 5% LF, EDE + 5% LF + TCP (once daily), and EDE + 5% LF + TCP (twice daily). Clinical parameters (tear volume, tear break-up time (TBUT), corneal fluorescein staining score (CFSS), tear film lipid layer grade (TFLLG)) were assessed on days 7 and 14. Goblet cell density in the conjunctiva, CD4+ IFN-γ+ T cells, interleukin levels, reactive oxygen species (ROS) levels, and corneal apoptotic cells were analyzed on day 14. Results: Monotherapy with 0.05% CsA and LF showed improvements in all clinical parameters compared to the EDE control (p < 0.05). Combination therapy groups demonstrated superior improvements in clinical parameters compared to the EDE control, 0.05% CsA, and 5% LF groups. CD4+ IFN-γ+ T cell percentages and ROS levels in the cornea and conjunctiva were markedly reduced in the combination groups compared with the 0.05% CsA and 5% LF groups (p < 0.01). Furthermore, corneal apoptotic cells significantly decreased in the combination groups compared to the 0.05% CsA and TCP groups (p < 0.05). Conclusions: Combined 5% LF and TCP eye drops improved tear film parameters and reduced inflammatory and oxidative stress markers. The combination therapy can mitigate ocular surface damage by managing inflammation and oxidative stress in dry eye.

29 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HYHyeon-Jeong Yoon
Hyeon-Jeong Yoon
JMJayoung Moon
Jayoung Moon
HKHyunjee Kim
Hyunjee Kim
SPSodam Park
Sodam Park
JCJi Suk Choi
Ji Suk Choi
KYKyung Chul Yoon
Kyung Chul Yoon
Background/Objectives: Sensitivity to ocular irritation varies among individuals, being influenced by clinical, subjective, and biochemical factors. This study aimed to evaluate individual variability in ocular irritation sensitivity, focusing on clinical parameters, pain perception, and tear neuromediator profiles. Methods: Sixty female participants aged 20–40 were classified into high-sensitivity and low-sensitivity groups based on their response to an irritant (Tween20). Clinical assessments included the ocular surface disease index (OSDI), tear break-up time (TBUT), Schirmer test, and corneal touch threshold measured with the Cochet–Bonnet esthesiometer. Pain sensitivity was assessed using the pain sensitivity questionnaire (PSQ), and tear neuromediators were quantified in tear samples before and after stimulation. The concentrations of calcitonin gene-related peptide (CGRP), nerve growth factor, neuropeptide Y, vasoactive intestinal peptide (VIP), and substance P were measured using an enzyme-linked immune sorbent assay (ELISA). Results: The high-sensitivity group exhibited significantly higher OSDI scores (p = 0.038). No significant differences were observed in TBUT, corneal staining scores, or Schirmer’s test results. The PSQ results revealed that the high-sensitivity group had lower total and moderate pain scores (p = 0.037 and p = 0.040, respectively). An analysis of the tear neuromediator showed elevated baseline CGRP levels (p = 0.017) and a significant post-stimulation increase in substance P (p = 0.021) in the high-sensitivity group. Conclusions: These findings emphasize the value of combining clinical, subjective, and biochemical measures to understand sensitivity to ocular irritation. This comprehensive approach may guide the development of safer cosmetic formulations and improve safety assessment protocols.

15 October 2023 in Journal of the Korean Ophthalmological Society
Verified
Journal Article
Open access
PDF file
HKHyun Jee Kim
Hyun Jee Kim
YJYong-Sok Ji
Yong-Sok Ji
KYKyung Chul Yoon
Kyung Chul Yoon
HYHyeon-Jeong Yoon
Hyeon-Jeong Yoon
Purpose: We assessed the clinical manifestations and prognostic factors associated with ocular infection in patients diagnosed with orbital and preseptal cellulitis.Methods: We enrolled 40 patients diagnosed with ocular infection accompanied by orbital and preseptal cellulitis between October 2015 and December 2021. We divided patients into the “treatment success group” (patients whose infection resolved) and the “treatment failure group” (patients whose infection worsened and required evisceration). Clinical characteristics, such as infection-related ocular findings and microbiological features, were analyzed retrospectively in both groups. Chi-square tests and logistic regression analyses were performed to identify prognostic factors associated with treatment failure.Results: The mean age of patients was 72.8 ± 11.92 years, with 17 (42.5%) of them being male. Among the patients, 11 had bacterial infections, and 3 had fungal infections. In total, 6 (15%) and 34 (85%) patients were classified into the treatment success and failure groups, respectively. The chi-square test revealed a significant association between the treatment failure group and several clinical factors, such as low best corrected visual acuity (BCVA), the logarithm of the minimum angle resolution (logMAR) BCVA > 2, low intraocular pressure (IOP) < 5 mmHg, large size of the corneal lesion, and the presence of hypopyon (p < 0.05). Furthermore, the multivariate logistic regression analysis identified hypopyon as a significant risk factor for treatment failure (p = 0.036).Conclusions: A significantly high treatment failure rate of 85% was observed in patients with ocular infections accompanied by orbital and preseptal cellulitis. Several clinical factors, such as low BCVA with logMAR BCVA > 2, IOP < 5 mmHg, large size of the corneal lesion, and a prolonged duration of symptoms demonstrated significant association with treatment failure. Notably, hypopyon is an important prognostic factor for treatment failure.

30 April 2026 in Korean Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
YCYe Ji Cho
Ye Ji Cho
HKHyun Jee Kim
Hyun Jee Kim
KYKyung Chul Yoon
Kyung Chul Yoon
HYHyeon-Jeong Yoon
Hyeon-Jeong Yoon

13 March 2026 in Medicine
Verified
Journal Article
Open access
HJHyo Ju Jang
Hyo Ju Jang
GSGa-young Song
Ga-young Song
SKSung Sun Kim
Sung Sun Kim
KYKyung-Chul Yoon
Kyung-Chul Yoon
HYHyeon-Jeong Yoon
Hyeon-Jeong Yoon
Rationale: Extramedullary relapse of acute lymphoblastic leukemia (ALL) involving the orbit is uncommon, and lacrimal gland infiltration is particularly rare in adults. Bilateral lacrimal gland enlargement can be clinically nonspecific and may be misinterpreted as inflammatory or autoimmune disease, potentially delaying diagnosis. This case report describes a rare adult case of extramedullary relapse of B-cell ALL presenting as bilateral lacrimal gland enlargement following allogeneic hematopoietic stem cell transplantation (HSCT). Patient concerns: A 55-year-old woman presented with a 4-day history of a painless, palpable mass in the right upper eyelid. The patient had a history of Philadelphia chromosome-negative B-cell ALL and had previously undergone chemotherapy followed by allogeneic HSCT. Diagnoses: Orbital computed tomography demonstrated diffuse, heterogeneous enlargement of both lacrimal glands, more prominent on the right side. Incisional biopsy of the right lacrimal gland with immunohistochemical staining (terminal deoxynucleotidyl transferase positive and B-lineage markers positive) confirmed extramedullary relapse of B-cell ALL. Interventions: The patient received salvage chemotherapy followed by a 2nd allogeneic HSCT. Outcomes: Follow-up orbital computed tomography performed 6 months after treatment showed complete resolution of bilateral lacrimal gland enlargement without evidence of local progression. Lessons: Bilateral lacrimal gland enlargement in patients with a history of ALL may represent isolated extramedullary relapse, even in the absence of hematologic abnormalities. Early histopathologic confirmation is essential to prevent diagnostic delay and to enable timely systemic management in ALL patients.